Prevalence of Viral Infections and Serious Complications in Pediatric Hematopoietic Stem Cell Transplant Patients: A Ten-Year Single-Institution Retrospective Study

Overview

Journal J Hematol

Specialty Hematology

Date 2025 Feb 12

PMID 39935700

Authors

Calvin E Lau

David J DiTullio

Holly Wilhalme

LaVette Bowles

Theodore B Moore

Satiro N De Oliveira

Affiliations

Soon will be listed here.

Abstract

Background: Pediatric hematopoietic stem cell transplant (pHSCT) patients are at risk for many life-threatening post-transplant complications, notably relapse, graft-versus-host disease (GvHD), and infection.

Methods: This retrospective study reviewed 10 years of pHSCT at a single institution, assessing for risk factors for post-transplantation viral infections (herpes simplex virus (HSV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpes virus 6 (HHV6), adenovirus (ADNV), and human polyoma virus 1 (BK virus)), and characterizing adverse infectious outcomes.

Results: Overall, 139 patients received 151 transplants. With respect to graft source: 73 (48.3%) were bone marrow, 67 (44.4%) umbilical cord blood (UCB), and 11 (7.2%) peripheral blood stem cells (PBSCs). Forty-one deaths occurred, for an overall mortality rate of 29.5%. The overall incidence of post-transplant viral infections was 47.7% (n = 72). Incidence of post-transplant infection varied by virus type: 3.97% HSV, 0.67% VZV, 3.97% EBV, 24.5% CMV, 14.5% HHV6, 12.6% ADNV, and 12.6% BK virus. Viral encephalitis, though relatively uncommon, was primarily caused by HHV6 and more common in UCB transplants. Overall, cell source and donor source were identified with statistically significant correlation to both risk of infection and mortality.

Conclusions: Post-transplant viral infection remains as a serious adverse event in pediatric patients, and thus prospective studies should be performed to implement early intervention and more aggressive treatment in select high-risk patients. More studies specifically addressing infection risks in cord blood transplants and risk factors for post-transplant viral encephalitis are warranted.

References

Anne de Pagter P, Schuurman R, Visscher H, de Vos M, Bierings M, van Loon A . Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. Biol Blood Marrow Transplant. 2008; 14(7):831-9. DOI: 10.1016/j.bbmt.2008.04.016. View

Ogata M, Oshima K, Ikebe T, Takano K, Kanamori H, Kondo T . Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017; 52(11):1563-1570. DOI: 10.1038/bmt.2017.175. View

Nagler A, Mohty M . In 2022, which is preferred: haploidentical or cord transplant?. Hematology Am Soc Hematol Educ Program. 2022; 2022(1):64-73. PMC: 9820258. DOI: 10.1182/hematology.2022000327. View

Costa A, Santos B, Torregrossa V, Miranda E, Vigorito A, Palmieri M . Oral shedding of CMV and HSV-1 in hematopoietic stem cell transplantation patients. Oral Dis. 2020; 27(6):1572-1579. DOI: 10.1111/odi.13690. View

Srinivasan A, Wang C, Srivastava D, Burnette K, Shenep J, Leung W . Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 19(1):94-101. PMC: 3554248. DOI: 10.1016/j.bbmt.2012.08.012. View

Peters C, Dalle J, Locatelli F, Poetschger U, Sedlacek P, Buechner J . Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2020; 39(4):295-307. PMC: 8078415. DOI: 10.1200/JCO.20.02529. View

Admiraal R, de Koning C, Lindemans C, Bierings M, Wensing A, Versluys A . Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation. J Allergy Clin Immunol. 2017; 140(6):1643-1650.e9. DOI: 10.1016/j.jaci.2016.12.992. View

Reed D, Petroni G, West M, Jones C, Alfaraj A, Williams P . Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation. Hematol Oncol Stem Cell Ther. 2023; 16(1):61-69. DOI: 10.1016/j.hemonc.2021.05.001. View

Hiwarkar P, Gaspar H, Gilmour K, Jagani M, Chiesa R, Bennett-Rees N . Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant. 2012; 48(6):803-8. DOI: 10.1038/bmt.2012.221. View

10.

Olkinuora H, Taskinen M, Saarinen-Pihkala U, Vettenranta K . Multiple viral infections post-hematopoietic stem cell transplantation are linked to the appearance of chronic GVHD among pediatric recipients of allogeneic grafts. Pediatr Transplant. 2009; 14(2):242-8. DOI: 10.1111/j.1399-3046.2009.01226.x. View

11.

Silcock R, Mitchell K, Fraser C, Clark J . Epidemiology and outcome for viremia in children undergoing bone marrow transplant: A retrospective cohort study. Transpl Infect Dis. 2021; 23(4):e13580. DOI: 10.1111/tid.13580. View

12.

Tsoumakas K, Giamaiou K, Goussetis E, Graphakos S, Kossyvakis A, Horefti E . Epidemiology of viral infections among children undergoing hematopoietic stem cell transplant: Α prospective single-center study. Transpl Infect Dis. 2019; 21(4):e13095. DOI: 10.1111/tid.13095. View

13.

Wu J, Ma H, Lu C, Chen J, Lee P, Jou S . Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients. J Microbiol Immunol Infect. 2015; 50(3):307-313. DOI: 10.1016/j.jmii.2015.07.011. View

14.

Gyurkocza B, Sandmaier B . Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014; 124(3):344-53. PMC: 4102707. DOI: 10.1182/blood-2014-02-514778. View

15.

Yalcin K, Pehlivan B, Celen S, Bas E, Kabakci C, Pashayev D . Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. J Pediatr Hematol Oncol. 2021; 43(7):266-270. DOI: 10.1097/MPH.0000000000002055. View

16.

Chen K, Cheng M, Hammond S, Einsele H, Marty F . Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv. 2018; 2(16):2159-2175. PMC: 6113617. DOI: 10.1182/bloodadvances.2018016493. View

17.

Matthes-Martin S, Lion T, Aberle S, Fritsch G, Lawitschka A, Bittner B . Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant. 2003; 31(9):803-8. DOI: 10.1038/sj.bmt.1703927. View

18.

Fisher B, Alexander S, Dvorak C, Zaoutis T, Zerr D, Sung L . Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. Pediatr Blood Cancer. 2011; 59(1):11-5. PMC: 4008326. DOI: 10.1002/pbc.23417. View

19.

Yamada M, Sakamoto K, Tomizawa D, Ishikawa Y, Matsui T, Gocho Y . A Prospective Viral Monitoring Study After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Nonmalignant Diseases. Transplant Cell Ther. 2021; 27(10):872.e1-872.e8. DOI: 10.1016/j.jtct.2021.07.014. View

20.

Duver F, Weissbrich B, Eyrich M, Wolfl M, Schlegel P, Wiegering V . Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis. PLoS One. 2020; 15(2):e0228451. PMC: 6999888. DOI: 10.1371/journal.pone.0228451. View